Over the latest trailing 12-month period, total return cagr is -2.50%. The comparable SPY value is +16.94%. Year-to-date total return is -36.21%. Total return includes price appreciation and reinvested dividends.
Over the past 12 months, Total Return CAGR is -2.50%. Total return includes dividends reinvested. The total return CAGR includes both price appreciation and dividends reinvested. This gives a more complete picture of the company's investment performance.
Maze Therapeutics, Inc. (MAZE)
Total Return growth vs the same calendar quarter one year earlier, last 4 comparable quarters.
Quarter-end value of $100 invested at the start of the available history, with dividends reinvested; the newest quarter may be quarter-to-date. Q4 2026 (2026-10-05): $165.71.
| Year | Total return for the year |
|---|---|
| 2026 (YTD) | -36.21% |
| Period | Period End | QoQ Return | YoY Return |
|---|---|---|---|
| Q4 2026 (QTD) | 2026-10-05 | -2.8% | -36.2% |
| Q3 2026 | 2026-09-30 | -8.9% | +4.8% |
| Q2 2026 | 2026-06-30 | -0.0% | +143.2% |
| Q1 2026 | 2026-03-31 | -28.0% | +171.1% |
| Q4 2025 | 2025-12-31 | +59.8% | N/A |
| Q3 2025 | 2025-09-30 | +111.3% | N/A |
| Q2 2025 | 2025-06-30 | +11.4% | N/A |
| Q1 2025 | 2025-03-31 |
| N/A |
| N/A |
Calendar returns: QoQ compares the prior calendar quarter; YoY compares the same calendar quarter a year earlier. The newest quarter is in progress (quarter-to-date).
